Skip to Content

MD Anderson Events

A Celebration of Cancer Immunotherapy & Jim Allison

A Celebration of Cancer Immunotherapy & Jim Allison

 This symposium celebrates the success of the field of checkpoint inhibition therapy and the 70th birthday of its founder Jim Allison. Dr. Allison has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. His visionary work unraveling the function of the immune checkpoint protein CTLA-4 paved the way for the clinical application of ipilimumab, the first immune checkpoint inhibitor approved by the FDA to treat any cancer. Since that time, at least five other checkpoint inhibitor therapies have been approved for use in several cancers. Dr. Allison’s work has touched the lives of countless individuals. He has inspired numerous researchers to study fundamental immunology and clinicians to use those findings to treat patients with previously incurable cancers. Most importantly, since 2009, his work has given the possibility of a permanent cure for the more than 38,000 metastatic melanoma patients treated with ipilimumab, many of whom he has met personally. This symposium will bring together the clinicians and basic science researchers who worked with Dr. Allison to make checkpoint inhibition therapy a reality for our patients and who continue to work with him to extend its benefits to help “Make Cancer History.” It is expected that in addition to honoring a great scientist, the symposium will kindle new opportunities for collaborative work in immune checkpoint inhibition therapy and potentially new breakthroughs in fundamental immunology.

Date: 8/3/18, 9am to 4pm
Time: 8/3/18, 9am to 4pm
Location: Hickey Auditorium, Main Building, Floor 11 (R11.1400)
Format: All Employee Meeting
Contact: Gloria Curtis - gacurtis@mdanderson.org